HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Atrial Natriuretic Factor (ANF)

Subscribe to New Research on Atrial Natriuretic Factor

A potent natriuretic and vasodilatory peptide or mixture of different-sized low molecular weight PEPTIDES derived from a common precursor and secreted mainly by the HEART ATRIUM. All these peptides share a sequence of about 20 AMINO ACIDS.

Also Known As:

ANF; ANP; ANF (1-126); ANF (1-28); ANF (99-126); ANF Precursors; ANP (1-126); ANP (1-28); ANP Prohormone (99-126); ANP-(99-126); Atrial Natriuretic Factor (1-126); Atrial Natriuretic Factor (1-28); Atrial Natriuretic Factor (99-126); Atrial Natriuretic Factor Precursors; Atrial Natriuretic Factor Prohormone; Atrial Natriuretic Peptide (1-126); Atrial Pronatriodilatin; Atriopeptigen; Atriopeptin (1-28); Atriopeptin (99-126); Atriopeptin 126; Atriopeptin Prohormone (1-126); Cardiodilatin (99-126); Cardiodilatin Precursor; Cardionatrin I; Cardionatrin IV; Prepro-ANP; Prepro-CDD-ANF; Prepro-Cardiodilatin-Atrial Natriuretic Factor; Pro-ANF; ProANF; Proatrial Natriuretic Factor; Pronatriodilatin; alpha ANP; alpha-ANP Dimer; alpha-Atrial Natriuretic Peptide; beta-ANP; beta-Atrial Natriuretic Peptide; gamma ANP (99-126); gamma-Atrial Natriuretic Peptide; Peptides, Atrial Natriuretic; Prepro ANP; Prepro CDD ANF; Prepro Cardiodilatin Atrial Natriuretic Factor; Pro ANF; alpha ANP Dimer; alpha Atrial Natriuretic Peptide; beta ANP; beta Atrial Natriuretic Peptide; gamma Atrial Natriuretic Peptide; Atrial Natriuretic Peptides; Atriopeptins; Auriculin; Natriuretic Peptides, Atrial; Atriopeptin

Networked: 4528 relevant articles (176 outcomes, 704 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Vesely, David L: 19 articles (04/2014 - 05/2002)
2.	Burnett, John C: 13 articles (09/2015 - 06/2002)
3.	Kuhn, Michaela: 13 articles (09/2014 - 11/2002)
4.	de Bold, Adolfo J: 13 articles (01/2014 - 03/2002)
5.	Volpe, Massimo: 12 articles (07/2014 - 04/2004)
6.	Rubattu, Speranza: 12 articles (07/2014 - 04/2004)
7.	Kim, Suhn Hee: 11 articles (07/2015 - 06/2003)
8.	Nakao, Kazuwa: 11 articles (03/2011 - 10/2003)
9.	Wu, Qingyu: 10 articles (09/2015 - 12/2003)
10.	Chen, Yiu-Fai: 10 articles (10/2011 - 02/2002)

Related Diseases

1.	Heart Failure 09/01/2008 - "SFX maintained the derangement of autonomic nerve control, blunted an increase in ANP in myocytes and plasma, and significantly improved survival in right heart failure and/or related organs dysfunction in PH rats. " 05/01/1999 - "The combination of ACEI and beta-blockers relieved symptoms and signs of heart failure in all 11 patients and significantly reduced atrial natriuretic protein (ANP) levels from 197.5 +/- 152.1 pg/mL to 25.5 +/- 16.2 pg/mL ( P <.002) at 15.5 +/- 8.2 months, brain natriuretic protein from 523.8 +/- 434.8 pg/mL to 59.3 +/- 24. " 11/01/1987 - "Although significantly reduced as compared to the control group, renal blood flow was not improved with ANP in the heart failure group. " 12/01/1990 - "Thus, in contrast to the considerable attenuation of renal effects of ANP-(99-126) in heart failure, the efficacy of ANP-(95-126) on renal excretory function is well preserved, which may be because of the lack of proteolytic degradation in the kidney. " 10/01/2013 - "Although the long-term infusion of ANP has proved effective to treat heart failure, no published randomized controlled study has been reported to confirm the efficacy of the short-term ANP infusion in congestive heart failure (CHF) patients. "
2.	Hypertension (High Blood Pressure) 12/01/2010 - "These results suggest that M-ANP, which is more potent than ANP in normal canines, has potent blood pressure lowering and renal enhancing properties and may, therefore, serve as an ANP based therapeutic for acute hypertension." 08/01/1990 - "With regard to its hemodynamic effects, ANP seems to be beneficial in patients with hypertension. " 04/01/2007 - "Our findings, while supporting previous experimental and clinical evidence of the antihypertrophic role of ANP in hypertension, may help to identify one of the possible mechanisms directly underlying LVH in MS." 10/01/1991 - "This article reviews data supporting hypothetical associations between ANF and essential hypertension, examines reports of plasma ANF concentrations in hypertension, discusses the efficacy of ANF and its analogs in the treatment of hypertension, and reviews future issues in ANF research. " 01/01/1980 - "After a 6-month follow-up period, three patients were cured of hypertension anf four showed improvement. "
3.	Pulmonary Hypertension (Ayerza Syndrome) 10/01/1999 - "Low-dose infusion (0.025 microg kg(-1) min(-1)) of synthetic human alpha-ANP infusion was very effective in improving the pulmonary hypertension." 01/01/1994 - "Results from our studies also indicate that selective ANP analogs and ET-AR antagonists may be clinically useful for the treatment of pulmonary hypertension." 01/01/2000 - "These results indicate that NO administration may be effective for preventing post-Pn pulmonary hypertension, although an elevation in ANP does not reduce the PAP." 12/01/1989 - "The data suggest that ANP is useful in the treatment of chronic hypoxic pulmonary hypertension in man." 03/20/2001 - "These results suggest that induction of ANP expression in the lung may hold promise in the treatment of pulmonary hypertension."
4.	Body Weight (Weight, Body) 01/01/2015 - "Confirming the gender dimorphism, FVB/N males (WM) illustrated a significant reduction in ANP and IL1-A levels as well as significantly increased body weight (BW (gm)), tibia length (TL (mm)), heart weight (HW (mg)), heart weight-to-body weight (HW/BW (mg/gm)) ratio, heart weight-to-tibia length (HW/TL (mg/mm)) ratio, left ventricle weight (LV (mg)), left ventricle-to-body weight (LV/BW (mg/gm)) ratio, and left ventricle-to-tibia length (LV/TL (mg/mm)) ratio, left ventricular (LV) cardiomyocyte diameter, high BNP, NPRA, IL-1B, and IL1R1 expression in comparison with FVB/N females (WF). " 09/01/1993 - "At the end of the dialytic process we observed a significant reduction of ANF plasma levels and body weight. " 09/01/1992 - "Plasma ANP levels after HD may help to adjust the right dry body weight for each patient." 01/01/2015 - "Rats were treated with 1.5 mL/100 g body weight of CQCQD (CQCQD group) or physiological saline (control and ANP groups) at 2 h interval. " 04/01/2013 - "The depletion group had higher heart-to-body weight ratio, and a trend towards higher ANP and BNP levels. "
5.	Hypertrophy 11/01/2002 - "This protection was achieved in the absence of a significant reduction in LV weight, but was accompanied by regression of myocyte hypertrophy, as reflected by reductions in cell size and ANF expression." 02/28/2014 - "Moreover, Anxa6 mutants that failed to associate with pro-ANP hindered ANP-mediated protection against hypertrophy, which was rescued, at least partially, by WT Anxa6. " 12/01/1995 - "2. In the present study, we prepared an in vitro model of cardiocyte hypertrophy using cultured neonatal rat ventricular cardiocytes and alpha1-adrenergic stimulation, and examined the gene expressions of BNP and ANP during the process of cardiocyte hypertrophy. " 03/01/1994 - "This study shows that in the normal heart induction of ANP synthesis by endurance training is not associated with ventricular hypertrophy. " 04/01/1992 - "Atrial myocytes serve as the principal source of ANF under physiological conditions, although recent studies have demonstrated that ventricular myocardium may also synthesize ANF in models of CHF associated with ventricular hypertrophy. "

Related Drugs and Biologics

1.	Atrial Natriuretic Factor (ANF)
2.	Messenger RNA (mRNA)
3.	Brain Natriuretic Peptide (Natrecor)
4.	Sodium
5.	Collagen
6.	Angiotensin II
7.	Adrenomedullin
8.	Creatinine
9.	Transforming Growth Factor beta (TGF-beta)
10.	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)

Related Therapies and Procedures

1.	Kidney Transplantation
2.	Electric Countershock (Cardioversion)
3.	Nephrectomy
4.	Renal Dialysis (Hemodialysis)
5.	Angioplasty (Angioplasty, Transluminal)